Amy Abernethy
Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices. In February, Roche paid US$1.9 billion to acquire Flatiron Health , a 6-year old health technolog...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2018-07, Vol.17 (7), p.462-464 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 464 |
|---|---|
| container_issue | 7 |
| container_start_page | 462 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 17 |
| description | Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.
In February,
Roche paid US$1.9 billion to acquire Flatiron Health
, a 6-year old health technology company that is working to transform oncology electronic health records into regulatory-grade real-world data. For Flatiron CSO and CMO Amy Abernethy — an oncologist and palliative care specialist by training who popularized the term 'financial toxicity' for expensive cancer drugs — this approach is already starting to streamline drug development and clinical trials in ways that are making waves across the health-care industry. Most notably, Flatiron's data set helped to speed up the reimbursement of Roche's ALK inhibitor alectinib by a year and a half. Abernethy spoke with Asher Mullard about how cleaned up and curated real-world data stand to transform clinical trials, drug regulation, competition in the health-care market and even drug prices. |
| doi_str_mv | 10.1038/nrd.2018.101 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2061407693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A544578314</galeid><sourcerecordid>A544578314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-743b652293ecf70d1a1c447d9ff97e6dc189b6bef1296638ae97fe4080e136733</originalsourceid><addsrcrecordid>eNptkLtPwzAQxi0EoqV0Y0ZILAyk-GLHjseo4iVVYoHZyuNcUuVR7GTof49DSytQ5eF85999-vwRcgV0BpTFD40tZiGF2HdwQsbAJQ9Axvx0f5diRC6cW1EKAmR4TkahUhGVVI3JNKk3N0mGtsHuc3NJzkxaOZzu6oR8PD2-z1-Cxdvz6zxZBDkPeRdIzjIRhaFimBtJC0gh51wWyhglURQ5xCoTGRoIlRAsTlFJg5zGFIEJydiE3G1117b96tF1ui5djlWVNtj2TodUAKdSqAG9_Yeu2t423t0PxaTgDA7UMq1Ql41pO5vmg6hOIs4jGTPgnpodofwpsC7ztkFT-vmfhfvtQm5b5ywavbZlndqNBqqH9LVPXw_p-25wcb3z2mc1Fnv4N24PBFvA-admifbwmaOC32zfiQ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2061376431</pqid></control><display><type>article</type><title>Amy Abernethy</title><source>Nature</source><source>SpringerNature Journals</source><description>Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.
In February,
Roche paid US$1.9 billion to acquire Flatiron Health
, a 6-year old health technology company that is working to transform oncology electronic health records into regulatory-grade real-world data. For Flatiron CSO and CMO Amy Abernethy — an oncologist and palliative care specialist by training who popularized the term 'financial toxicity' for expensive cancer drugs — this approach is already starting to streamline drug development and clinical trials in ways that are making waves across the health-care industry. Most notably, Flatiron's data set helped to speed up the reimbursement of Roche's ALK inhibitor alectinib by a year and a half. Abernethy spoke with Asher Mullard about how cleaned up and curated real-world data stand to transform clinical trials, drug regulation, competition in the health-care market and even drug prices.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd.2018.101</identifier><identifier>PMID: 29950709</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154 ; 631/154/109 ; 631/154/155 ; 631/154/2426 ; 692/308/153 ; Abernethy, Amy ; an-audience-with ; Biomedicine ; Biotechnology ; Cancer Research ; Clinical trials ; Drug development ; Electronic health records ; Interviews ; Medicinal Chemistry ; Molecular Medicine ; Officials and employees ; Oncologists ; Oncology ; Pharmaceutical industry ; Pharmacology/Toxicology</subject><ispartof>Nature reviews. Drug discovery, 2018-07, Vol.17 (7), p.462-464</ispartof><rights>Springer Nature Limited 2018</rights><rights>COPYRIGHT 2018 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jul 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-743b652293ecf70d1a1c447d9ff97e6dc189b6bef1296638ae97fe4080e136733</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrd.2018.101$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrd.2018.101$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29950709$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><title>Amy Abernethy</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><description>Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.
In February,
Roche paid US$1.9 billion to acquire Flatiron Health
, a 6-year old health technology company that is working to transform oncology electronic health records into regulatory-grade real-world data. For Flatiron CSO and CMO Amy Abernethy — an oncologist and palliative care specialist by training who popularized the term 'financial toxicity' for expensive cancer drugs — this approach is already starting to streamline drug development and clinical trials in ways that are making waves across the health-care industry. Most notably, Flatiron's data set helped to speed up the reimbursement of Roche's ALK inhibitor alectinib by a year and a half. Abernethy spoke with Asher Mullard about how cleaned up and curated real-world data stand to transform clinical trials, drug regulation, competition in the health-care market and even drug prices.</description><subject>631/154</subject><subject>631/154/109</subject><subject>631/154/155</subject><subject>631/154/2426</subject><subject>692/308/153</subject><subject>Abernethy, Amy</subject><subject>an-audience-with</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>Drug development</subject><subject>Electronic health records</subject><subject>Interviews</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Officials and employees</subject><subject>Oncologists</subject><subject>Oncology</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology/Toxicology</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkLtPwzAQxi0EoqV0Y0ZILAyk-GLHjseo4iVVYoHZyuNcUuVR7GTof49DSytQ5eF85999-vwRcgV0BpTFD40tZiGF2HdwQsbAJQ9Axvx0f5diRC6cW1EKAmR4TkahUhGVVI3JNKk3N0mGtsHuc3NJzkxaOZzu6oR8PD2-z1-Cxdvz6zxZBDkPeRdIzjIRhaFimBtJC0gh51wWyhglURQ5xCoTGRoIlRAsTlFJg5zGFIEJydiE3G1117b96tF1ui5djlWVNtj2TodUAKdSqAG9_Yeu2t423t0PxaTgDA7UMq1Ql41pO5vmg6hOIs4jGTPgnpodofwpsC7ztkFT-vmfhfvtQm5b5ywavbZlndqNBqqH9LVPXw_p-25wcb3z2mc1Fnv4N24PBFvA-admifbwmaOC32zfiQ0</recordid><startdate>20180701</startdate><enddate>20180701</enddate><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180701</creationdate><title>Amy Abernethy</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-743b652293ecf70d1a1c447d9ff97e6dc189b6bef1296638ae97fe4080e136733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>631/154</topic><topic>631/154/109</topic><topic>631/154/155</topic><topic>631/154/2426</topic><topic>692/308/153</topic><topic>Abernethy, Amy</topic><topic>an-audience-with</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>Drug development</topic><topic>Electronic health records</topic><topic>Interviews</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Officials and employees</topic><topic>Oncologists</topic><topic>Oncology</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology/Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amy Abernethy</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>17</volume><issue>7</issue><spage>462</spage><epage>464</epage><pages>462-464</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.
In February,
Roche paid US$1.9 billion to acquire Flatiron Health
, a 6-year old health technology company that is working to transform oncology electronic health records into regulatory-grade real-world data. For Flatiron CSO and CMO Amy Abernethy — an oncologist and palliative care specialist by training who popularized the term 'financial toxicity' for expensive cancer drugs — this approach is already starting to streamline drug development and clinical trials in ways that are making waves across the health-care industry. Most notably, Flatiron's data set helped to speed up the reimbursement of Roche's ALK inhibitor alectinib by a year and a half. Abernethy spoke with Asher Mullard about how cleaned up and curated real-world data stand to transform clinical trials, drug regulation, competition in the health-care market and even drug prices.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29950709</pmid><doi>10.1038/nrd.2018.101</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2018-07, Vol.17 (7), p.462-464 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2061407693 |
| source | Nature; SpringerNature Journals |
| subjects | 631/154 631/154/109 631/154/155 631/154/2426 692/308/153 Abernethy, Amy an-audience-with Biomedicine Biotechnology Cancer Research Clinical trials Drug development Electronic health records Interviews Medicinal Chemistry Molecular Medicine Officials and employees Oncologists Oncology Pharmaceutical industry Pharmacology/Toxicology |
| title | Amy Abernethy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T03%3A44%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amy%20Abernethy&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.date=2018-07-01&rft.volume=17&rft.issue=7&rft.spage=462&rft.epage=464&rft.pages=462-464&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd.2018.101&rft_dat=%3Cgale_proqu%3EA544578314%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2061376431&rft_id=info:pmid/29950709&rft_galeid=A544578314&rfr_iscdi=true |